{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:55:17Z","timestamp":1753880117272,"version":"3.41.2"},"reference-count":47,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,9,21]]},"abstract":"<jats:p>\n            ME1100 (arbekacin inhalation solution) is an inhaled aminoglycoside that is being developed to treat patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP, respectively). Pharmacokinetic-pharmacodynamic (PK-PD) target attainment analyses were undertaken to evaluate ME1100 regimens for the treatment of patients with HABP\/VABP. The data used included a population pharmacokinetic (PPK) 4-compartment model with 1st-order elimination, nonclinical PK-PD targets from one-compartment\n            <jats:italic>in vitro<\/jats:italic>\n            and\/or\n            <jats:italic>in vivo<\/jats:italic>\n            infection models, and\n            <jats:italic>in vitro<\/jats:italic>\n            surveillance data.\n          <\/jats:p>","DOI":"10.1128\/aac.02367-19","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T14:23:01Z","timestamp":1594736581000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation Solution"],"prefix":"10.1128","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4891-6467","authenticated-orcid":false,"given":"Sujata M.","family":"Bhavnani","sequence":"first","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey P.","family":"Hammel","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Lakota","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Courtney","family":"Safir","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6527-1475","authenticated-orcid":false,"given":"Brian D.","family":"VanScoy","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Nagira","sequence":"additional","affiliation":[{"name":"Meiji Seika Pharma Co., Ltd., Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M.","family":"Rubino","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuo","family":"Sato","sequence":"additional","affiliation":[{"name":"Meiji Seika Pharma Co., Ltd., Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomokazu","family":"Koresawa","sequence":"additional","affiliation":[{"name":"Meiji Seika Pharma Co., Ltd., Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichiro","family":"Kondo","sequence":"additional","affiliation":[{"name":"Meiji Seika Pharma Co., Ltd., Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul G.","family":"Ambrose","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/00000542-200104000-00005","article-title":"Is ventilator-associated pneumonia an independent risk factor for death?","volume":"94","author":"Bregeon F","year":"2001","unstructured":"Bregeon F, Ciais V, Carret V, Gregoire R, Saux P, Gainnier M, Thirion X, Drancourt M, Auffray JP, Papazian L. 2001. Is ventilator-associated pneumonia an independent risk factor for death? Anesthesiology 94:554\u2013560.","journal-title":"Anesthesiology"},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1378\/chest.120.2.555","article-title":"The occurrence of ventilator-associated pneumonia in a community hospital: risk factors and clinical outcomes","volume":"120","author":"Ibrahim EH","year":"2001","unstructured":"Ibrahim EH, Tracy L, Hill C, Fraser VJ, Kollef MH. 2001. The occurrence of ventilator-associated pneumonia in a community hospital: risk factors and clinical outcomes. Chest 120:555\u2013561.","journal-title":"Chest"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.122.6.2115"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000181731.53912.D9"},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00134-010-1824-6","article-title":"Attributable mortality of ventilator-associated pneumonia: respective impact of main characteristics at ICU admission and VAP onset using conditional logistic regression and multi-state models","volume":"36","author":"Nguile-Makao N","year":"2010","unstructured":"Nguile-Makao N, Zahar J-R, Francais A, Tabah A, Garrouste-Orgeas M, Allaouchiche B, Goldgran-Toledano D, Azoulay E, Adrie C, Jamali S, Clec'h C, Souweine B, Timsit J-F. 2010. Attributable mortality of ventilator-associated pneumonia: respective impact of main characteristics at ICU admission and VAP onset using conditional logistic regression and multi-state models. Intensive Care Med 36:781\u2013789.","journal-title":"Intensive Care Med"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-012-1605-y"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.196377"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3182a2770f"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.23736\/S0375-9393.17.12198-X"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.159.4.9807050"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000063087.93157.06"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201105-0867OC"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-013-0407-1"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70081-1"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw353"},{"key":"e_1_3_3_17_2","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.chest.2017.04.162","article-title":"Burden of adult community-acquired, health-care-associated, hospital-acquired, and ventilator-associated pneumonia","volume":"152","author":"Corrado RE","year":"2020","unstructured":"Corrado RE, Lee D, Lucero DE, Varma JK, Vora NM. 2020. Burden of adult community-acquired, health-care-associated, hospital-acquired, and ventilator-associated pneumonia. Chest 152:930\u2013942.","journal-title":"Chest"},{"key":"e_1_3_3_18_2","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/infdis\/jiy578","article-title":"Evidence-based study design for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia","volume":"219","author":"Talbot GH","year":"2019","unstructured":"Talbot GH, Das A, Cush S, Dane A, Wible M, Echols R, Torres A, Cammarata S, Rex JH, Powers JH, Fleming T, Loutit J, Hoffman S. 2019. Evidence-based study design for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. J Infect Dis 219:1536\u20131544.","journal-title":"J Infect Dis"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/653060"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/664049"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1384752"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/653057"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.09.009"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.09.019"},{"key":"e_1_3_3_25_2","first-page":"349","article-title":"Antibacterial activities of arbekacin, a new aminoglycoside antibiotic, against methicillin-cephem-resistant Staphylococcus aureus","volume":"40","author":"Watanabe T","year":"1987","unstructured":"Watanabe T, Goi H, Hara T, Sugano T, Tanaka Y, Kazuno Y, Matsuhashi Y, Yamamoto H, Yokota T. 1987. Antibacterial activities of arbekacin, a new aminoglycoside antibiotic, against methicillin-cephem-resistant Staphylococcus aureus. Jpn J Antibiot 40:349\u2013356.","journal-title":"Jpn J Antibiot"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2013.45.1.62"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-012-0519-z"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S44377"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04839-14"},{"key":"e_1_3_3_30_2","volume-title":"Arbekacin (ABK) package insert. Version 7","author":"Meiji Seika Kaisha","year":"2011","unstructured":"Meiji Seika Kaisha. 2011. Arbekacin (ABK) package insert. Version 7. Meiji Seika Kaisha, Ltd., Tokyo, Japan."},{"key":"e_1_3_3_31_2","volume-title":"Abstr 54th Intersci Conf Antimicrob Agents Chemother","author":"VanScoy BD","year":"2014","unstructured":"VanScoy BD, McCauley J, Conde H, Baba N, Ouchi S, Forrest A, Trang M, Bhavnani SM, Ambrose PG. 2014. Does the inhalational delivery method for aminoglycosides change the pharmacokinetic-pharmacodynamic index associated with efficacy? Abstr A-1184. Abstr 54th Intersci Conf Antimicrob Agents Chemother, 5 to 9 September 2014, Washington, DC."},{"key":"e_1_3_3_32_2","volume-title":"Abstr ASM Microbe 2017","author":"VanScoy BD","year":"2017","unstructured":"VanScoy BD, Lakota EA, Bhavnani SM, McCauley J, Nagira Y, Ouchi S, Ambrose PG. 2017. Identification of the arbekacin pharmacokinetic-pharmacodynamic targets associated with efficacy and the prevention of the amplification of Pseudomonas aeruginosa-resistant subpopulations after administration of ME1100 inhalation solution. Abstr 2017-A-2295-Microbe. Abstr ASM Microbe 2017, 1 to 5 June 2017, New Orleans, LA."},{"key":"e_1_3_3_33_2","volume-title":"Abstr ASM-ECCMID 2018","author":"Nagira Y","year":"2018","unstructured":"Nagira Y, Ouchi S, Okade H, Ida T, Kondo K, VanScoy B, Ambrose P. 2018. Evaluation of the pharmacokinetics-pharmacodynamics (PK\/PD) indices of ME1100 (arbekacin inhalation solution) against Pseudomonas aeruginosa in a murine lung infection model. Poster P0267. Abstr ASM-ECCMID 2018, 21 to 24 April 2018, Madrid, Spain."},{"key":"e_1_3_3_34_2","volume-title":"Abstr ASM Microbe 2017","author":"VanScoy BD","year":"2017","unstructured":"VanScoy BD, Lakota EA, Bhavnani SM, Jones C, Nagira Y, Ouchi S, Ambrose PG. 2017. Identification of the arbekacin pharmacokinetic-pharmacodynamic targets associated with efficacy and the prevention of the amplification of drug-resistant methicillin-resistant Staphylococcus aureus subpopulations after administration of ME1100 inhalation solution. Abstr 2017-A-2297-Microbe. Abstr ASM Microbe 2017, 1 to 5 June 2017, New Orleans, LA."},{"key":"e_1_3_3_35_2","unstructured":"Ouchi S Aoki M Kamiyabu S Vutikullird A Gorfried M Ishihama T. 2014. Safety tolerability systemic and pulmonary pharmacokinetics of arbekacin following ME1100 inhalation in healthy volunteers. Abstr F-1614. Abstr 54th Intersci Conf Antimicrob Agents Chemother 5 to 9 September 2014 Washington DC."},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.13-22.2001"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.9.3944-3947.2005"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01680-13"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00267-19"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.8.1.58"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00480-05"},{"key":"e_1_3_3_42_2","first-page":"98","article-title":"Population pharmacokinetic analysis of arbekacin sulfate in adult patients","volume":"27","author":"Sato N","year":"2010","unstructured":"Sato N, Miura Y, Mitomi N, Hayashi H, Suzuki H, Shibasaki S. 2010. Population pharmacokinetic analysis of arbekacin sulfate in adult patients. Jpn J Ther Drug Monit 27:98\u2013110.","journal-title":"Jpn J Ther Drug Monit"},{"key":"e_1_3_3_43_2","volume-title":"Microbiology data for systemic antibacterial drug products\u2014development, analysis, and presentation: guidance for industry","author":"FDA","year":"2018","unstructured":"FDA. 2018. Microbiology data for systemic antibacterial drug products\u2014development, analysis, and presentation: guidance for industry. Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD."},{"key":"e_1_3_3_44_2","volume-title":"45th Intersci Conf Antimicrob Agents Chemother","author":"Ambrose PG","year":"2005","unstructured":"Ambrose PG, Bhavnani SM, Rubino CM, Jones RN, Drusano GL. 2005. Susceptibility breakpoint decision support: use of Monte Carlo simulation and bootstrapping to establish minimum bacterial isolate samples. Poster A-1834. 45th Intersci Conf Antimicrob Agents Chemother, 16 to 19 December 2005, Washington, DC."},{"key":"e_1_3_3_45_2","volume-title":"R: a language and environment for statistical computing","author":"R Development Core Team","year":"2014","unstructured":"R Development Core Team. 2014. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria."},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1916.00080130010002"},{"key":"e_1_3_3_48_2","volume-title":"Abstr 53rd Intersci Conf Antimicrob Agents Chemother","author":"Bulik CC","year":"2013","unstructured":"Bulik CC, Bhavnani SM, Hammel J, Forrest A, Dudley MN, Ellis-Grosse EJ, Drusano GL, Ambrose PG. 2013. Relationship between regulatory approval and pharmacokinetic-pharmacodynamic target attainment: focus on community- and hospital-acquired pneumonia. Abstr A-295. Abstr 53rd Intersci Conf Antimicrob Agents Chemother, 10 to 13 September 2013, Denver, CO."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02367-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02367-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:35:33Z","timestamp":1645486533000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02367-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,21]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,9,21]]}},"alternative-id":["10.1128\/AAC.02367-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.02367-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2020,9,21]]},"assertion":[{"value":"2019-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02367-19"}}